Adeno-Associated Viruses (AAVs)

Introduction

Adeno-Associated Viruses (AAVs) are small, generally non-pathogenic viruses used as vectors for delivering therapeutic genes into specific cells, making them important tools in modern gene therapy and biotechnology.

Causative Factors and Biological Characteristics

1. Viral nature: AAVs are generally considered non-pathogenic in humans and are primarily significant for their applications in gene therapy rather than as direct causes of human disease.
2. Association with adenoviruses: AAVs were initially identified in association with adenoviruses and generally require a helper virus, such as an adenovirus or herpesvirus, for productive replication.
3. Genetic defects: The diseases treated using AAV-based therapies often arise from mutations or defects in genes responsible for producing essential proteins, enzymes or other functional molecules.
4. Underlying disease mechanisms: Depending on the disorder, genetic mutations may cause the absence of a functional protein, production of a defective protein or disruption of normal cellular processes.
5. Limitations of natural AAVs: Their natural biology does not automatically make them suitable for therapy; scientists engineer AAV vectors to improve gene delivery, tissue targeting and safety.

Therapeutic Treatments and Applications

1. Gene replacement therapy: Engineered AAV vectors deliver a functional copy of a defective or missing gene into target cells, enabling them to produce the required protein and potentially address the underlying cause of certain inherited disorders.
2. Retinal disorders: AAV-based gene therapy is used to treat certain inherited retinal diseases by delivering functional genetic material to retinal cells, helping preserve or improve visual function in eligible patients.
3. Neurological disorders: AAV vectors are being investigated for delivering therapeutic genes to the brain and nervous system, with potential applications in selected inherited neurological and neurodegenerative disorders.
4. Optogenetics: AAVs can deliver genes encoding light-sensitive proteins into specific neurons, enabling researchers to activate or inhibit neural activity using light and investigate brain circuits involved in memory, emotions and behaviour.
5. Muscular disorders: AAV-based gene therapies are used or investigated for selected genetic muscle diseases by delivering genes that enable cells to produce essential proteins.
6. Blood and metabolic disorders: Researchers are exploring AAV-mediated gene delivery for selected inherited disorders involving blood-clotting proteins and metabolic pathways, although suitability depends on the disease and therapeutic approach.
7. Precision medicine: Different AAV serotypes can be selected or engineered to improve delivery to particular tissues, including the liver, eye, muscles and nervous system, supporting more targeted treatment strategies.

Conclusion

AAVs have transformed viruses from potential biological threats into precision tools for therapeutic gene delivery. Their growing role in treating inherited and neurological disorders highlights the potential of biotechnology to move from symptom management towards addressing diseases at their genetic origin.